Camille Bedrosian Sells 10,028 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille Bedrosian sold 10,028 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the sale, the insider owned 278,064 shares of the company’s stock, valued at approximately $9,009,273.60. The trade was a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Amylyx Pharmaceuticals Trading Down 1.5%

AMLX stock opened at $33.15 on Wednesday. The firm has a market cap of $3.69 billion, a PE ratio of -23.18 and a beta of -0.13. The stock has a 50-day moving average price of $26.31 and a 200-day moving average price of $19.13. Amylyx Pharmaceuticals, Inc. has a 1-year low of $10.83 and a 1-year high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMLX. BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $158,534,000. Jupiter Topco LLC purchased a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at $94,014,000. Commodore Capital LP lifted its stake in Amylyx Pharmaceuticals by 38.6% during the 4th quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock valued at $68,252,000 after acquiring an additional 1,574,522 shares in the last quarter. Siren L.L.C. purchased a new position in Amylyx Pharmaceuticals during the 1st quarter worth $17,097,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth $18,912,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. HC Wainwright increased their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Guggenheim increased their target price on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Finally, Robert W. Baird raised their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $38.86.

About Amylyx Pharmaceuticals